Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 63 entries
Sorted by: Best Match Show Resources per page
Corrigendum to "Epicutaneous immunization with phosphorylcholine conjugated to bovine serum albumin (PC-BSA) and TLR9 ligand CpG alleviates pneumococcal pneumonia in mice" [Pharmacol. Rep. 66 (2014) 570-575].

Pharmacological reports : PR

Majewska-Szczepanik M, Yamamoto N, Askenase PW, Szczepanik M.
PMID: 28365257
Pharmacol Rep. 2017 Jun;69(3):584. doi: 10.1016/j.pharep.2017.01.014. Epub 2017 Mar 29.

No abstract available.

Cite
Majewska-Szczepanik M, Yamamoto N, Askenase PW, et al. Corrigendum to "Epicutaneous immunization with phosphorylcholine conjugated to bovine serum albumin (PC-BSA) and TLR9 ligand CpG alleviates pneumococcal pneumonia in mice" [Pharmacol. Rep. 66 (2014) 570-575]. Pharmacol Rep. 2017;69(3):584doi: 10.1016/j.pharep.2017.01.014.
Majewska-Szczepanik, M., Yamamoto, N., Askenase, P. W., & Szczepanik, M. (2017). Corrigendum to "Epicutaneous immunization with phosphorylcholine conjugated to bovine serum albumin (PC-BSA) and TLR9 ligand CpG alleviates pneumococcal pneumonia in mice" [Pharmacol. Rep. 66 (2014) 570-575]. Pharmacological reports : PR, 69(3), 584. https://doi.org/10.1016/j.pharep.2017.01.014
Majewska-Szczepanik, Monika, et al. "Corrigendum to "Epicutaneous immunization with phosphorylcholine conjugated to bovine serum albumin (PC-BSA) and TLR9 ligand CpG alleviates pneumococcal pneumonia in mice" [Pharmacol. Rep. 66 (2014) 570-575]." Pharmacological reports : PR vol. 69,3 (2017): 584. doi: https://doi.org/10.1016/j.pharep.2017.01.014
Majewska-Szczepanik M, Yamamoto N, Askenase PW, Szczepanik M. Corrigendum to "Epicutaneous immunization with phosphorylcholine conjugated to bovine serum albumin (PC-BSA) and TLR9 ligand CpG alleviates pneumococcal pneumonia in mice" [Pharmacol. Rep. 66 (2014) 570-575]. Pharmacol Rep. 2017 Jun;69(3):584. doi: 10.1016/j.pharep.2017.01.014. Epub 2017 Mar 29. PMID: 28365257.
Copy Download .nbib Format: NLM
Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments.

Lupus science & medicine

Askanase A, Li X, Pong A, Shum K, Kamp S, Carthen F, Aberle T, Hanrahan L, Daly P, Giles J, Merrill JT.
PMID: 25861457
Lupus Sci Med. 2015 Mar 04;2(1):e000075. doi: 10.1136/lupus-2014-000075. eCollection 2015.

OBJECTIVE: Current disease activity measures for systemic lupus erythematosus (SLE) are difficult to score or interpret and problematic for use in clinical practice. Lupus Foundation of America (LFA)-Rapid Evaluation of Activity in Lupus (REAL) is a pilot application composed...

Cite
Askanase A, Li X, Pong A, et al. Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. Lupus Sci Med. 2015;2(1):e000075doi: 10.1136/lupus-2014-000075.
Askanase, A., Li, X., Pong, A., Shum, K., Kamp, S., Carthen, F., Aberle, T., Hanrahan, L., Daly, P., Giles, J., & Merrill, J. T. (2015). Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. Lupus science & medicine, 2(1), e000075. https://doi.org/10.1136/lupus-2014-000075
Askanase, Anca, et al. "Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments." Lupus science & medicine vol. 2,1 (2015): e000075. doi: https://doi.org/10.1136/lupus-2014-000075
Askanase A, Li X, Pong A, Shum K, Kamp S, Carthen F, Aberle T, Hanrahan L, Daly P, Giles J, Merrill JT. Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. Lupus Sci Med. 2015 Mar 04;2(1):e000075. doi: 10.1136/lupus-2014-000075. eCollection 2015. PMID: 25861457; PMCID: PMC4378376.
Copy Download .nbib Format: NLM
Myocarditis in systemic lupus erythematosus diagnosed by .

Lupus science & medicine

Perel-Winkler A, Bokhari S, Perez-Recio T, Zartoshti A, Askanase A, Geraldino-Pardilla L.
PMID: 30094040
Lupus Sci Med. 2018 Jul 12;5(1):e000265. doi: 10.1136/lupus-2018-000265. eCollection 2018.

OBJECTIVES: Cardiovascular diseaseand heart failure (CHF) are leading causes of death in systemic lupus erythematosus (SLE). The underlying mechanisms for increased CHF in SLE are unclear but myocardial inflammation and lupus myocarditis (LM) may play a role. We propose...

Cite
Perel-Winkler A, Bokhari S, Perez-Recio T, et al. Myocarditis in systemic lupus erythematosus diagnosed by . Lupus Sci Med. 2018;5(1):e000265doi: 10.1136/lupus-2018-000265.
Perel-Winkler, A., Bokhari, S., Perez-Recio, T., Zartoshti, A., Askanase, A., & Geraldino-Pardilla, L. (2018). Myocarditis in systemic lupus erythematosus diagnosed by . Lupus science & medicine, 5(1), e000265. https://doi.org/10.1136/lupus-2018-000265
Perel-Winkler, Alexandra, et al. "Myocarditis in systemic lupus erythematosus diagnosed by ." Lupus science & medicine vol. 5,1 (2018): e000265. doi: https://doi.org/10.1136/lupus-2018-000265
Perel-Winkler A, Bokhari S, Perez-Recio T, Zartoshti A, Askanase A, Geraldino-Pardilla L. Myocarditis in systemic lupus erythematosus diagnosed by . Lupus Sci Med. 2018 Jul 12;5(1):e000265. doi: 10.1136/lupus-2018-000265. eCollection 2018. PMID: 30094040; PMCID: PMC6069920.
Copy Download .nbib Format: NLM
The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data.

Rheumatology and therapy

Tang W, Khalili L, Giles J, Gartshteyn Y, Kapoor T, Guo C, Chen T, Theodore D, Askanase A.
PMID: 34028704
Rheumatol Ther. 2021 Jun;8(2):681-691. doi: 10.1007/s40744-021-00315-x. Epub 2021 May 24.

Since the first outbreak of Coronavirus Disease-2019 (COVID-19) in January 2020, the medical community has been pursuing effective countermeasures. Early in the pandemic, several small clinical and in vitro studies from France and China reported on the efficacy of...

Cite
Tang W, Khalili L, Giles J, et al. The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. Rheumatol Ther. 2021;8(2):681-691doi: 10.1007/s40744-021-00315-x.
Tang, W., Khalili, L., Giles, J., Gartshteyn, Y., Kapoor, T., Guo, C., Chen, T., Theodore, D., & Askanase, A. (2021). The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. Rheumatology and therapy, 8(2), 681-691. https://doi.org/10.1007/s40744-021-00315-x
Tang, Wei, et al. "The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data." Rheumatology and therapy vol. 8,2 (2021): 681-691. doi: https://doi.org/10.1007/s40744-021-00315-x
Tang W, Khalili L, Giles J, Gartshteyn Y, Kapoor T, Guo C, Chen T, Theodore D, Askanase A. The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. Rheumatol Ther. 2021 Jun;8(2):681-691. doi: 10.1007/s40744-021-00315-x. Epub 2021 May 24. PMID: 34028704; PMCID: PMC8142615.
Copy Download .nbib Format: NLM
Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort.

Rheumatology (Oxford, England)

Chew C, Reynolds JA, Lertratanakul A, Wu P, Urowitz M, Gladman DD, Fortin PR, Bae SC, Gordon C, Clarke AE, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guerrero J, Romero-Diaz J, Merrill J, Wallace D, Ginzler E, Khamashta M, Nived O, Jönsen A, Steinsson K, Manzi S, Kalunian K, Dooley MA, Petri M, Aranow C, van Vollenhoven R, Stoll T, Alarcón GS, Lim SS, Ruiz-Irastorza G, Peschken CA, Askanase AD, Kamen DL, İnanç M, Ramsey-Goldman R, Bruce IN.
PMID: 33555325
Rheumatology (Oxford). 2021 Oct 02;60(10):4737-4747. doi: 10.1093/rheumatology/keab090.

OBJECTIVES: Vitamin D (25(OH)D) deficiency and metabolic syndrome (MetS) may both contribute to increased cardiovascular risk in SLE. We aimed to examine the association of demographic factors, SLE phenotype, therapy and vitamin D levels with MetS and insulin resistance.METHODS:...

Cite
Chew C, Reynolds JA, Lertratanakul A, et al. Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology (Oxford). 2021;60(10):4737-4747doi: 10.1093/rheumatology/keab090.
Chew, C., Reynolds, J. A., Lertratanakul, A., Wu, P., Urowitz, M., Gladman, D. D., Fortin, P. R., Bae, S. C., Gordon, C., Clarke, A. E., Bernatsky, S., Hanly, J. G., Isenberg, D., Rahman, A., Sanchez-Guerrero, J., Romero-Diaz, J., Merrill, J., Wallace, D., Ginzler, E., Khamashta, M., Nived, O., Jönsen, A., Steinsson, K., Manzi, S., Kalunian, K., Dooley, M. A., Petri, M., Aranow, C., van Vollenhoven, R., Stoll, T., Alarcón, G. S., Lim, S. S., Ruiz-Irastorza, G., Peschken, C. A., Askanase, A. D., Kamen, D. L., İnanç, M., Ramsey-Goldman, R., & Bruce, I. N. (2021). Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology (Oxford, England), 60(10), 4737-4747. https://doi.org/10.1093/rheumatology/keab090
Chew, Christine, et al. "Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort." Rheumatology (Oxford, England) vol. 60,10 (2021): 4737-4747. doi: https://doi.org/10.1093/rheumatology/keab090
Chew C, Reynolds JA, Lertratanakul A, Wu P, Urowitz M, Gladman DD, Fortin PR, Bae SC, Gordon C, Clarke AE, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guerrero J, Romero-Diaz J, Merrill J, Wallace D, Ginzler E, Khamashta M, Nived O, Jönsen A, Steinsson K, Manzi S, Kalunian K, Dooley MA, Petri M, Aranow C, van Vollenhoven R, Stoll T, Alarcón GS, Lim SS, Ruiz-Irastorza G, Peschken CA, Askanase AD, Kamen DL, İnanç M, Ramsey-Goldman R, Bruce IN. Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology (Oxford). 2021 Oct 02;60(10):4737-4747. doi: 10.1093/rheumatology/keab090. PMID: 33555325; PMCID: PMC8487307.
Copy Download .nbib Format: NLM
Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.

Lupus science & medicine

Putterman C, Furie R, Ramsey-Goldman R, Askanase A, Buyon J, Kalunian K, Chatham WW, Massarotti E, Kirou K, Jordan N, Blanco I, Weinstein A, Chitkara P, Manzi S, Ahearn J, O'Malley T, Conklin J, Ibarra C, Barken D, Dervieux T.
PMID: 25396070
Lupus Sci Med. 2014 Oct 01;1(1):e000056. doi: 10.1136/lupus-2014-000056. eCollection 2014.

OBJECTIVE: To compare the performance characteristics of cell-bound complement (C4d) activation products (CBCAPS) on erythrocyte (EC4d) and B cells (BC4d) with antibodies to double-stranded DNA (anti-dsDNA) and complement C3 and C4 in systemic lupus erythematosus (SLE).METHODS: The study enrolled...

Cite
Putterman C, Furie R, Ramsey-Goldman R, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci Med. 2014;1(1):e000056doi: 10.1136/lupus-2014-000056.
Putterman, C., Furie, R., Ramsey-Goldman, R., Askanase, A., Buyon, J., Kalunian, K., Chatham, W. W., Massarotti, E., Kirou, K., Jordan, N., Blanco, I., Weinstein, A., Chitkara, P., Manzi, S., Ahearn, J., O'Malley, T., Conklin, J., Ibarra, C., Barken, D., & Dervieux, T. (2014). Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus science & medicine, 1(1), e000056. https://doi.org/10.1136/lupus-2014-000056
Putterman, Chaim, et al. "Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements." Lupus science & medicine vol. 1,1 (2014): e000056. doi: https://doi.org/10.1136/lupus-2014-000056
Putterman C, Furie R, Ramsey-Goldman R, Askanase A, Buyon J, Kalunian K, Chatham WW, Massarotti E, Kirou K, Jordan N, Blanco I, Weinstein A, Chitkara P, Manzi S, Ahearn J, O'Malley T, Conklin J, Ibarra C, Barken D, Dervieux T. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci Med. 2014 Oct 01;1(1):e000056. doi: 10.1136/lupus-2014-000056. eCollection 2014. PMID: 25396070; PMCID: PMC4225732.
Copy Download .nbib Format: NLM
Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients.

F1000Research

Li X, Golubovsky J, Hui-Yuen J, Shah U, Olech E, Lomeo R, Singh V, Busch H, Strandberg MJ, Strandberg K, Horowitz L, Askanase A.
PMID: 27158444
F1000Res. 2015 Oct 23;4:1103. doi: 10.12688/f1000research.7192.1. eCollection 2015.

OBJECTIVES: Acthar Gel is a long-acting formulation of adrenocorticotropic hormone (ACTH) with anti-inflammatory effects thought to be mediated in part through melanocortin receptor activation. This study was initiated to understand the role of Acthar Gel in SLE treatment in...

Cite
Li X, Golubovsky J, Hui-Yuen J, et al. Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients. F1000Res. 2015;4:1103doi: 10.12688/f1000research.7192.1.
Li, X., Golubovsky, J., Hui-Yuen, J., Shah, U., Olech, E., Lomeo, R., Singh, V., Busch, H., Strandberg, M. J., Strandberg, K., Horowitz, L., & Askanase, A. (2015). Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients. F1000Research, 41103. https://doi.org/10.12688/f1000research.7192.1
Li, Xiao, et al. "Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients." F1000Research vol. 4 (2015): 1103. doi: https://doi.org/10.12688/f1000research.7192.1
Li X, Golubovsky J, Hui-Yuen J, Shah U, Olech E, Lomeo R, Singh V, Busch H, Strandberg MJ, Strandberg K, Horowitz L, Askanase A. Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients. F1000Res. 2015 Oct 23;4:1103. doi: 10.12688/f1000research.7192.1. eCollection 2015. PMID: 27158444.
Copy Download .nbib Format: NLM
Lupus community panel proposals for optimising clinical trials: 2018.

Lupus science & medicine

Merrill JT, Manzi S, Aranow C, Askanase A, Bruce I, Chakravarty E, Chong B, Costenbader K, Dall'Era M, Ginzler E, Hanrahan L, Kalunian K, Merola J, Raymond S, Rovin B, Saxena A, Werth VP.
PMID: 29657738
Lupus Sci Med. 2018 Mar 23;5(1):e000258. doi: 10.1136/lupus-2018-000258. eCollection 2018.

Formidable impediments stand in the way of treatment development for lupus. These include the unwieldy size of current trials, international competition for scarce patients, complex outcome measures and a poor understanding of these outcomes in the world at large....

Cite
Merrill JT, Manzi S, Aranow C, et al. Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci Med. 2018;5(1):e000258doi: 10.1136/lupus-2018-000258.
Merrill, J. T., Manzi, S., Aranow, C., Askanase, A., Bruce, I., Chakravarty, E., Chong, B., Costenbader, K., Dall'Era, M., Ginzler, E., Hanrahan, L., Kalunian, K., Merola, J., Raymond, S., Rovin, B., Saxena, A., & Werth, V. P. (2018). Lupus community panel proposals for optimising clinical trials: 2018. Lupus science & medicine, 5(1), e000258. https://doi.org/10.1136/lupus-2018-000258
Merrill, Joan T, et al. "Lupus community panel proposals for optimising clinical trials: 2018." Lupus science & medicine vol. 5,1 (2018): e000258. doi: https://doi.org/10.1136/lupus-2018-000258
Merrill JT, Manzi S, Aranow C, Askanase A, Bruce I, Chakravarty E, Chong B, Costenbader K, Dall'Era M, Ginzler E, Hanrahan L, Kalunian K, Merola J, Raymond S, Rovin B, Saxena A, Werth VP. Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci Med. 2018 Mar 23;5(1):e000258. doi: 10.1136/lupus-2018-000258. eCollection 2018. PMID: 29657738; PMCID: PMC5894527.
Copy Download .nbib Format: NLM
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.

Annals of the rheumatic diseases

Almeida-Brasil CC, Hanly JG, Urowitz M, Clarke AE, Ruiz-Irastorza G, Gordon C, Ramsey-Goldman R, Petri M, Ginzler EM, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim S, van Vollenhoven RF, Nived O, Jönsen A, Kamen DL, Aranow C, Sanchez-Guerrero J, Gladman DD, Fortin PR, Alarcón GS, Merrill JT, Kalunian K, Ramos-Casals M, Steinsson K, Zoma A, Askanase A, Khamashta MA, Bruce IN, Inanc M, Abrahamowicz M, Bernatsky S.
PMID: 34911705
Ann Rheum Dis. 2021 Dec 15; doi: 10.1136/annrheumdis-2021-221295. Epub 2021 Dec 15.

OBJECTIVES: To evaluate systemic lupus erythematosus (SLE) flares following hydroxychloroquine (HCQ) reduction or discontinuation versus HCQ maintenance.METHODS: We analysed prospective data from the Systemic Lupus International Collaborating Clinics (SLICC) cohort, enrolled from 33 sites within 15 months of SLE...

Cite
Almeida-Brasil CC, Hanly JG, Urowitz M, et al. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-221295.
Almeida-Brasil, C. C., Hanly, J. G., Urowitz, M., Clarke, A. E., Ruiz-Irastorza, G., Gordon, C., Ramsey-Goldman, R., Petri, M., Ginzler, E. M., Wallace, D. J., Bae, S. C., Romero-Diaz, J., Dooley, M. A., Peschken, C., Isenberg, D., Rahman, A., Manzi, S., Jacobsen, S., Lim, S., van Vollenhoven, R. F., Nived, O., Jönsen, A., Kamen, D. L., Aranow, C., Sanchez-Guerrero, J., Gladman, D. D., Fortin, P. R., Alarcón, G. S., Merrill, J. T., Kalunian, K., Ramos-Casals, M., Steinsson, K., Zoma, A., Askanase, A., Khamashta, M. A., Bruce, I. N., Inanc, M., Abrahamowicz, M., & Bernatsky, S. (2021). Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-221295
Almeida-Brasil, Celline C, et al. "Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-221295
Almeida-Brasil CC, Hanly JG, Urowitz M, Clarke AE, Ruiz-Irastorza G, Gordon C, Ramsey-Goldman R, Petri M, Ginzler EM, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim S, van Vollenhoven RF, Nived O, Jönsen A, Kamen DL, Aranow C, Sanchez-Guerrero J, Gladman DD, Fortin PR, Alarcón GS, Merrill JT, Kalunian K, Ramos-Casals M, Steinsson K, Zoma A, Askanase A, Khamashta MA, Bruce IN, Inanc M, Abrahamowicz M, Bernatsky S. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2021 Dec 15; doi: 10.1136/annrheumdis-2021-221295. Epub 2021 Dec 15. PMID: 34911705.
Copy Download .nbib Format: NLM
Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI).

Arthritis care & research

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin PR, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG.
PMID: 33152181
Arthritis Care Res (Hoboken). 2020 Nov 05; doi: 10.1002/acr.24504. Epub 2020 Nov 05.

OBJECTIVE: The Systemic Lupus International Collaborating Clinics (SLICC) frailty index (FI) predicts mortality and damage accrual in SLE, but its association with hospitalizations has not been described. We estimated the association of baseline SLICC-FI values with future hospitalizations in...

Cite
Legge A, Kirkland S, Rockwood K, et al. Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). Arthritis Care Res (Hoboken). 2020;doi: 10.1002/acr.24504.
Legge, A., Kirkland, S., Rockwood, K., Andreou, P., Bae, S. C., Gordon, C., Romero-Diaz, J., Sanchez-Guerrero, J., Wallace, D. J., Bernatsky, S., Clarke, A. E., Merrill, J. T., Ginzler, E. M., Fortin, P. R., Gladman, D. D., Urowitz, M. B., Bruce, I. N., Isenberg, D. A., Rahman, A., Alarcón, G. S., Petri, M., Khamashta, M. A., Dooley, M. A., Ramsey-Goldman, R., Manzi, S., Zoma, A. A., Aranow, C., Mackay, M., Ruiz-Irastorza, G., Lim, S. S., Inanc, M., van Vollenhoven, R. F., Jonsen, A., Nived, O., Ramos-Casals, M., Kamen, D. L., Kalunian, K. C., Jacobsen, S., Peschken, C. A., Askanase, A., & Hanly, J. G. (2020). Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). Arthritis care & research, . https://doi.org/10.1002/acr.24504
Legge, Alexandra, et al. "Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI)." Arthritis care & research vol. (2020). doi: https://doi.org/10.1002/acr.24504
Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin PR, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG. Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). Arthritis Care Res (Hoboken). 2020 Nov 05; doi: 10.1002/acr.24504. Epub 2020 Nov 05. PMID: 33152181; PMCID: PMC8096857.
Copy Download .nbib Format: NLM
Response to: 'Phsician's global assessment is often useful in SLE, but not always: the case of clinical remission' by Zen .

Annals of the rheumatic diseases

Askanase A, Oon S, Huq M, Calderone A, Morand EF, Nikpour M, Aranow C.
PMID: 32434819
Ann Rheum Dis. 2020 May 20; doi: 10.1136/annrheumdis-2020-217687. Epub 2020 May 20.

No abstract available.

Cite
Askanase A, Oon S, Huq M, et al. Response to: 'Phsician's global assessment is often useful in SLE, but not always: the case of clinical remission' by Zen . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-217687.
Askanase, A., Oon, S., Huq, M., Calderone, A., Morand, E. F., Nikpour, M., & Aranow, C. (2020). Response to: 'Phsician's global assessment is often useful in SLE, but not always: the case of clinical remission' by Zen . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-217687
Askanase, Anca, et al. "Response to: 'Phsician's global assessment is often useful in SLE, but not always: the case of clinical remission' by Zen ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-217687
Askanase A, Oon S, Huq M, Calderone A, Morand EF, Nikpour M, Aranow C. Response to: 'Phsician's global assessment is often useful in SLE, but not always: the case of clinical remission' by Zen . Ann Rheum Dis. 2020 May 20; doi: 10.1136/annrheumdis-2020-217687. Epub 2020 May 20. PMID: 32434819.
Copy Download .nbib Format: NLM
Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Rheumatology and therapy

Askanase AD, Zhao E, Zhu J, Bilyk R, Furie RA.
PMID: 32996096
Rheumatol Ther. 2020 Dec;7(4):893-908. doi: 10.1007/s40744-020-00236-1. Epub 2020 Sep 29.

INTRODUCTION: We assessed the efficacy and safety of repository corticotropin injection (RCI; ActharMETHODS: This multicenter, double-blind, randomized, placebo-controlled study enrolled patients ≥ 18 years with active SLE and moderate to severe rash and/or arthritis despite stable glucocorticoid doses (7.5-30...

Cite
Askanase AD, Zhao E, Zhu J, et al. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Rheumatol Ther. 2020;7(4):893-908doi: 10.1007/s40744-020-00236-1.
Askanase, A. D., Zhao, E., Zhu, J., Bilyk, R., & Furie, R. A. (2020). Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Rheumatology and therapy, 7(4), 893-908. https://doi.org/10.1007/s40744-020-00236-1
Askanase, Anca D, et al. "Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial." Rheumatology and therapy vol. 7,4 (2020): 893-908. doi: https://doi.org/10.1007/s40744-020-00236-1
Askanase AD, Zhao E, Zhu J, Bilyk R, Furie RA. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Rheumatol Ther. 2020 Dec;7(4):893-908. doi: 10.1007/s40744-020-00236-1. Epub 2020 Sep 29. PMID: 32996096; PMCID: PMC7695765.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 63 entries